Research Notes
Compound guides, protocol breakdowns, and what the science actually says about the peptides we carry.
No marketing language. We cover the compounds we stock so you can make informed decisions.
Latest Research
8 ArticlesSemax et NAD+ contre le déclin cognitif lié à la perte osseuse sous GLP-1
Pourquoi cette question se pose maintenant Les agonistes du récepteur GLP-1, comme le sémaglutide et le tirzépatide, ont transformé la prise en...
Dihexa après un AVC ischémique : récupération cognitive avec P21 et NAD+
Le Dihexa, le P21 et le NAD+ suscitent l'espoir pour la récupération cognitive après un AVC ischémique, mais les preuves cliniques manquent....
Semax as an Adjunct to GLP-1-Based Therapies: Preserving Cognitive Function Amid Medicare's Expanded Coverage
Medicare's expanded GLP-1 coverage raises questions about cognitive side effects. We examine the evidence for Semax as an adjunct to preserve brain
Dihexa et protection cognitive lors de perte osseuse GLP-1
La convergence des risques : ménopause, GLP-1 et déclin cognitif Les agonistes du récepteur GLP-1 offrent des résultats remarquables pour la gestion
Semax Dosing Protocols to Counter GLP-1 Cognitive Side Effects
Current research on Semax dosing to counter GLP-1 cognitive side effects reveals significant gaps. No direct trials exist, only extrapolations from unrelated...
Dihexa Neuroprotection During Tirzepatide Weight Loss
Examining the evidence for Dihexa neuroprotection during Tirzepatide-induced weight loss reveals large gaps: no human data, no metabolic context studies, only theory.
Semax for Cognitive Resilience During Tirzepatide Treatment
Current research on Semax for cognitive support during tirzepatide treatment shows mechanistic promise but lacks direct clinical evidence in weight loss populations.
Dihexa for Cognitive Protection During GLP-1 Weight Loss
Current research on dihexa's neuroprotective potential during GLP-1 weight loss remains largely preclinical, with human evidence nearly absent despite mechanistic promise.